Driving Innovation And Performance While Reducing Cost Of Goods In Drug Production
Purolite’s Senior Director of Product Management, Renato Azevedo, and the Purolite team announced the launch of Purolite’s latest innovation, DurA Cycle, at the recent BIO International Convention in San Diego. Renato shared insight into the latest addition to Purolite’s resin toolbox.
"We're seeing a shift in the pharmaceutical industry, with drug manufacturers aiming to reduce bioburden by using more intense cleaning regimes. Reducing bioburden is critical to increasing purity in yields.
However, protein A resins have traditionally been unable to maintain performance across numerous cycles under these conditions – presenting a significant challenge to therapeutic drug developers.
Ecolab is committed to progressing pharmaceutical innovation and supporting therapeutic drug developers bringing life changing medicines to patients. This commitment to innovation can be seen across Purolite, particularly in the advancement of Purolite’s product roadmap.
In the last 18 months, Purolite has announced the release of three new affinity chromatography resins, including DurA Cycle.
DurA Cycle reduces pressure on downstream purification, helping manufacturers improve process economics while supporting sustainability goals. A combination of higher caustic and protease resistance ensures a longer resin lifetime, reducing operating costs and increasing target molecule output.
Due to the milder elution of DurA Cycle, greater HCPs, DNA, and other impurities are removed. This reduces the burden on the next chromatography steps. Utilizing DurA Cycle can help drug manufacturers reduce, remove, or replace more expensive steps within the protein purification process."
Source: Ecolab, Purolite Resins